Tirzepatide, a GLP-1 receptor agonist, was approved by the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) in 2023 for weight loss, helping patients feel fuller longer.

Susan McGowan, a 58-year-old nurse from North Lanarkshire, tragically died on September 4, 2024, after taking two low-dose injections of Mounjaro, the brand name for tirzepatide.

Her death certificate indicated that multiple organ failure, septic shock, and pancreatitis were contributing factors, with Mounjaro noted as a potential cause.

The MHRA's yellow card scheme reported 208 adverse effects related to tirzepatide from January to May 2024, including one suspected death prior to McGowan's case.

In light of the ongoing obesity crisis, the UK government is set to conduct a five-year trial in Greater Manchester, providing Mounjaro to nearly 250,000 unemployed individuals to assist in their return to work.

The Scottish Government has expressed sympathy for those affected by McGowan's death, emphasizing that prescribing decisions are made by local health boards and healthcare professionals.

Following her second injection, McGowan experienced severe stomach pains and was hospitalized, where she ultimately went into organ failure despite efforts from her colleagues.

Eli Lilly, the manufacturer of Mounjaro, emphasized its commitment to patient safety and ongoing monitoring of its products, while expressing condolences to McGowan's family.

Her niece, Jade Campbell, described McGowan as a healthy and vibrant person without prior health concerns, expressing shock at her rapid decline after starting the medication.

Dr. Alison Cave from the MHRA has stated that while monitoring new medications for safety is crucial, the benefits of GLP-1 receptor agonists generally outweigh the risks when used correctly.

Mounjaro, priced between £150 and £200 for a four-week supply, is currently in a phased rollout by the NHS, but its availability is limited due to high demand and capacity constraints.

Concerns about the safety of GLP-1 receptor agonists are heightened by data showing 23 suspected deaths linked to another drug in the class, semaglutide, since 2019.